GlassScriptPhysician profile
John R Denning
NPI 1508818246
$1,823.83
in general payments reported to CMS, 2019-2025
25 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $28.25 · 2021: $22.50 · 2022: $49.95 · 2023: $414 · 2024: $227 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $337.76 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $224.67 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Alnylam Pharmaceuticals INC. | $146.21 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $105.48 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.48 | 2019 | |
| Novo Nordisk INC | $97.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $84.19 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $78.54 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $68.64 | 2021-2025 | |
| Lilly USA, LLC | $67.99 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $59.69 | 2025 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $55.32 | 2019 | |
| Sanofi Pasteur INC. | $52.70 | 2025 | |
| Inspire Medical Systems, INC. | $46.45 | 2023 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $40.57 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $26.23 | 2019-2020 | |
| Gilead Sciences, INC. | $25.31 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.52 | 2022 | |
| Phadia US INC. | $15.63 | 2024 | Immunocap |
| Therapeuticsmd, INC. | $13.62 | 2019 | |
| Cranial Technologies, INC | $13.07 | 2020 | |
| Daiichi Sankyo INC. | $13.02 | 2019 | |
| Radius Health, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Denning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.